CO2021002395A2 - Antagonistas de integrina - Google Patents

Antagonistas de integrina

Info

Publication number
CO2021002395A2
CO2021002395A2 CONC2021/0002395A CO2021002395A CO2021002395A2 CO 2021002395 A2 CO2021002395 A2 CO 2021002395A2 CO 2021002395 A CO2021002395 A CO 2021002395A CO 2021002395 A2 CO2021002395 A2 CO 2021002395A2
Authority
CO
Colombia
Prior art keywords
integrin antagonists
antagonists
medicament
formula
integrin
Prior art date
Application number
CONC2021/0002395A
Other languages
English (en)
Inventor
Ove Pedersen
Elke Vermassen
Original Assignee
Oxurion NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxurion NV filed Critical Oxurion NV
Publication of CO2021002395A2 publication Critical patent/CO2021002395A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos antagonistas de integrina de Fórmula I y su uso como medicamento, en particular para inhibir la neovascularización.
CONC2021/0002395A 2018-08-17 2021-02-24 Antagonistas de integrina CO2021002395A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18189615 2018-08-17
EP18194258 2018-09-13
PCT/EP2019/072185 WO2020043533A1 (en) 2018-08-17 2019-08-19 Integrin antagonists

Publications (1)

Publication Number Publication Date
CO2021002395A2 true CO2021002395A2 (es) 2021-07-30

Family

ID=67659335

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0002395A CO2021002395A2 (es) 2018-08-17 2021-02-24 Antagonistas de integrina

Country Status (22)

Country Link
US (2) US10703752B2 (es)
EP (2) EP3613739B1 (es)
JP (1) JP7083073B2 (es)
KR (1) KR20210057735A (es)
CN (1) CN112805284A (es)
AU (1) AU2019326932A1 (es)
BR (1) BR112021002839A2 (es)
CA (1) CA3109326A1 (es)
CO (1) CO2021002395A2 (es)
CY (1) CY1123871T1 (es)
DK (1) DK3613739T3 (es)
ES (1) ES2836733T3 (es)
HU (1) HUE051802T2 (es)
IL (1) IL280857A (es)
LT (1) LT3613739T (es)
MA (1) MA53218A (es)
MX (1) MX2021001786A (es)
RS (1) RS61182B1 (es)
SG (1) SG11202101424XA (es)
SI (1) SI3613739T1 (es)
WO (1) WO2020043533A1 (es)
ZA (1) ZA202101406B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240015737A (ko) 2018-10-30 2024-02-05 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
CN116059312A (zh) * 2021-07-23 2023-05-05 百奥泰生物制药股份有限公司 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
CN118356501A (zh) * 2023-01-19 2024-07-19 百奥泰生物制药股份有限公司 一种复方制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
WO2015175954A1 (en) 2014-05-16 2015-11-19 Scifluor Life Sciences, Inc. Alpha v integrin antagonist compositions

Also Published As

Publication number Publication date
EP3613739B1 (en) 2020-11-04
IL280857A (en) 2021-04-29
HUE051802T2 (hu) 2021-03-29
SG11202101424XA (en) 2021-03-30
EP3613739A1 (en) 2020-02-26
US20200055849A1 (en) 2020-02-20
US10703752B2 (en) 2020-07-07
LT3613739T (lt) 2021-02-25
CY1123871T1 (el) 2022-03-24
EP3837257A1 (en) 2021-06-23
BR112021002839A2 (pt) 2021-05-11
RS61182B1 (sr) 2021-01-29
MA53218A (fr) 2022-04-20
MX2021001786A (es) 2021-07-02
ZA202101406B (en) 2022-07-27
CN112805284A (zh) 2021-05-14
DK3613739T3 (en) 2020-12-07
SI3613739T1 (sl) 2021-02-26
JP2021534252A (ja) 2021-12-09
JP7083073B2 (ja) 2022-06-09
WO2020043533A1 (en) 2020-03-05
AU2019326932A1 (en) 2021-03-18
ES2836733T3 (es) 2021-06-28
KR20210057735A (ko) 2021-05-21
CA3109326A1 (en) 2020-03-05
US20210198258A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CO2021002395A2 (es) Antagonistas de integrina
UY38140A (es) Picolinamidas como fungicidas
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
UY36491A (es) Picolinamidas con actividad fungicida
CO2017006920A2 (es) Picolinamidas como fungicidas
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
BR112019005464A2 (pt) antagonistas de trpv4
EA201691194A1 (ru) Стимуляторы ргц
UY35764A (es) El uso de picolinamidas macrociclicas como fungicidas.
UY35762A (es) Uso de picolinamidas macrocíclicas como fungicidas
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO2019012957A2 (es) Inhibidores de quinasa y usos de los mismos
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
BR112019005416A2 (pt) antagonistas de trpv4
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
GT201500012A (es) Derivados de carbamato/urea
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017002090A2 (pt) formulação de fator viii
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos